If neither Wegovy nor Zepbound is covered, we evaluate other FDA-approved options that may be on your formulary including Saxenda, Contrave, or phentermine
In February, Lars Fruergaard Jorgensen, the chief executive of Ozempic maker Novo Nordisk, said food company leaders had called him because they were scared. The question is, how widespread is Ozempic going to become? said Simeon Siegel, an analyst at BMO Capital Markets
However, as Exercise NZ notes: while fat loss is indeed happening, for many users this comes at the cost of lean muscle mass loss of muscle that underpins strength, metabolism, immune function and long-term resilience
How this renal protection occurs is still unknown
One of the most critical areas of emerging research in these chronic, post-viral illnesses revolves around cellular energy, systemic inflammation, and the body's ability to clear toxic byproducts